SAN DIEGO, December 09, 2025--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
As of April 8, 2026, sentiment around Gossamer Bio, Inc. (NASDAQ:GOSS) remains cautious, with 56% of covering analysts issuing "Hold" ratings on the stock. The consensus price target of $1 implies an ...
SAN FRANCISCO, May 5, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or ...
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Gossamer Bio, Inc. (“Gossamer” or the “Company” ...
A Gossamer Bio drug designed to penetrate into the central nervous system (CNS) to treat a rare cancer affecting the brain and spinal cord is discontinuing clinical development after reports of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results